Divalproex Sodium Tablet, Delayed Release
Product Images NDC 68084-776

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68084-776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

250 mg Blister

Labels for Divalproex Sodium Delayed-Release Tablet, USP, 250 mg strength. Each label shows the drug name, strength, delayed-release tablet form, a barcode, lot number, expiry date, and the labeler American Health Packaging in Columbus, Ohio. Multiple identical labels are arranged in a 2 by 5 grid.*

FDA Label Image

250 mg Carton

Label for Divalproex Sodium Delayed-Release Tablets, USP, 250 mg strength with valproic acid activity, packaged as 100 tablets (10 x 10). The label includes NDC 68084-776-01 and states the product is Rx only. It features storage instructions, a pharmacist dispensing note, and distributor information for American Health Packaging, Columbus, Ohio.*

FDA Label Image

500 mg Blister

This image displays a sheet of multiple barcode labels for Divalproex Sodium Delayed-Release Tablets, 500 mg strength. Each label includes the product name, strength, barcode, and batch details including a placeholder for lot number and expiry date. The labels also note the labeler as American Health Packaging, Columbus, Ohio.*

FDA Label Image

500 mg Carton

Divalproex Sodium delayed-release tablets, 500 mg strength with valproic acid activity, in a package of 90 tablets (9 x 10). The label includes NDC 68084-782-61 and indicates prescription use only. It is distributed by American Health Packaging, Columbus, Ohio.*

FDA Label Image

Ahp77601

Divalproex Sodium 250 mg or 500 mg extended-release tablets, capsule-shaped and scored, reddish-orange in color. One side is imprinted with the code 'D 85'. Labeler is American Health Packaging. Appropriate for prescription use.*

FDA Label Image

Ahp78261

Image of two oblong, purplish-pink tablets, one imprinted with "D 86" and the other plain. These tablets correspond to Divalproex Sodium, available in 250 mg and 500 mg strengths, as labeled by American Health Packaging.*

FDA Label Image

Figure 1

A bar chart labeled Figure 1 comparing the percentage outcomes of two studies involving divalproex sodium delayed-release tablets (DVPX) versus placebo (PBO). Study 1 (YMRS) shows 26% for placebo and 60% for DVPX. Study 2 (MRS) shows 29% for placebo and 58% for DVPX, with a note indicating statistical significance (p < 0.05).*

FDA Label Image

Figure 2

A line graph labeled Figure 2 comparing the percent reduction in CPS rate for Divalproex Sodium Delayed-Release Tablets versus placebo. The graph shows improvement and worsening on the vertical axis and percent of patients on the horizontal axis, with Divalproex Sodium having a solid line and placebo represented by a dashed line.*

FDA Label Image

Figure 3

A figure showing a cumulative distribution curve illustrating the percent reduction in CPS (Complex Partial Seizure) rate versus the percent of patients. It compares the effect of high dose (solid line) and low dose (dashed line) Divalproex Sodium, with the y-axis indicating improvement or worsening and the x-axis showing the percent of patients.*

FDA Label Image

Figure 4

A bar graph titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between Placebo and Divalproex Sodium Delayed-Release Tablets groups in two studies. The y-axis ranges from 0 to 6. Study 1 shows higher rates for Placebo compared to Divalproex Sodium, Study 2 similarly compares the two groups. Footnotes provide dosing information for the Divalproex Sodium Delayed-Release Tablets.*

FDA Label Image

Structure

Chemical structure of divalproex sodium depicted as a repeating polymer unit containing sodium salt and carboxylate groups linked to branched alkyl chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.